MX2009009862A - Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico. - Google Patents
Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico.Info
- Publication number
- MX2009009862A MX2009009862A MX2009009862A MX2009009862A MX2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A
- Authority
- MX
- Mexico
- Prior art keywords
- core
- byweight
- active principle
- withrespect
- amounts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Una forma de dosificación de liberación prolongada/pulsátil en un tiempo específico que comprende; un núcleo que comprende al menos un principio activo y al menos un agente desintegrante; una capa selladora que rodea el núcleo que esencialmente consiste de uno o más polímeros independientes de pH insolubles o solubles en agua; un revestimiento exterior esencialmente que consiste de uno o más polímeros independientes de pH; en donde: al menos un agente desintegrante es presente en cantidades de 1-20% por peso y al menos un principio activo es presente en cantidades de 1-80% por peso, con relación al núcleo; la capa selladora se representa en 0.1-10% por peso, con relación al núcleo; el revestimiento exterior se representa en 5-500% por peso, con relación al núcleo. Estos núcleos cubiertos son capaces de asegurar la liberación inmediata del principio activo después de un intervalo de tiempo pre-definido, independientemente de las variaciones de pH fisiológicas que ocurren en el tracto gastrointestinal de los mamíferos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07104213A EP1970056A1 (en) | 2007-03-15 | 2007-03-15 | Time-specific delayed/pulsatile release dosage forms |
PCT/EP2008/052957 WO2008110577A1 (en) | 2007-03-15 | 2008-03-12 | Time- specific delayed/pulsatile release dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009009862A true MX2009009862A (es) | 2009-12-14 |
Family
ID=38063792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009862A MX2009009862A (es) | 2007-03-15 | 2008-03-12 | Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100028426A1 (es) |
EP (2) | EP1970056A1 (es) |
JP (1) | JP2010521437A (es) |
KR (1) | KR20090119986A (es) |
CN (1) | CN101636153A (es) |
AR (1) | AR065778A1 (es) |
BR (1) | BRPI0808801A2 (es) |
CA (1) | CA2679210A1 (es) |
MX (1) | MX2009009862A (es) |
RU (1) | RU2452472C2 (es) |
WO (1) | WO2008110577A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009144558A1 (en) | 2008-04-18 | 2009-12-03 | Intec Pharma Ltd. | Carbidopa/lipodopa gastroretentive drug delivery |
US9693981B2 (en) * | 2008-12-04 | 2017-07-04 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
WO2010075080A1 (en) * | 2008-12-15 | 2010-07-01 | Somnus Therapeutics, Inc. | A method of treating insomnia |
CN103816130B (zh) * | 2014-01-22 | 2016-01-20 | 悦康药业集团有限公司 | 一种盐酸二甲双胍缓释片 |
WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
DE69222006T2 (de) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten |
AU3949093A (en) * | 1992-03-31 | 1993-11-08 | Benzon Pharma A/S | A pharmaceutical formulation |
GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
CO4920215A1 (es) * | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
DE60003194T2 (de) * | 1999-08-26 | 2004-06-17 | Neurocrine Biosciences, Inc., San Diego | Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren |
WO2001080824A2 (en) * | 2000-04-19 | 2001-11-01 | Eurand America, Inc. | Dual mechanism timed release dosage forms for low dose drugs |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US20060257482A1 (en) * | 2002-06-07 | 2006-11-16 | Patrik Kumar | Modified release, multiple unit drug delivery systems |
US20050038042A1 (en) * | 2002-11-15 | 2005-02-17 | Jenet Codd | Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
JP2007509155A (ja) * | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
US20090196889A1 (en) * | 2004-11-22 | 2009-08-06 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
US20080260818A1 (en) * | 2005-03-28 | 2008-10-23 | Dexcel Pharma Technologies Ltd. | Controlled Absorption of Statins in the Intestine |
WO2006102964A2 (en) * | 2005-03-29 | 2006-10-05 | Evonik Röhm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
US20060280795A1 (en) * | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
-
2007
- 2007-03-15 EP EP07104213A patent/EP1970056A1/en not_active Withdrawn
-
2008
- 2008-03-12 US US12/450,201 patent/US20100028426A1/en not_active Abandoned
- 2008-03-12 BR BRPI0808801-2A patent/BRPI0808801A2/pt not_active IP Right Cessation
- 2008-03-12 KR KR1020097020728A patent/KR20090119986A/ko not_active Application Discontinuation
- 2008-03-12 CN CN200880008426A patent/CN101636153A/zh active Pending
- 2008-03-12 EP EP08717703A patent/EP2120888A1/en not_active Withdrawn
- 2008-03-12 WO PCT/EP2008/052957 patent/WO2008110577A1/en active Application Filing
- 2008-03-12 RU RU2009138048/15A patent/RU2452472C2/ru not_active IP Right Cessation
- 2008-03-12 MX MX2009009862A patent/MX2009009862A/es not_active Application Discontinuation
- 2008-03-12 CA CA002679210A patent/CA2679210A1/en not_active Abandoned
- 2008-03-12 JP JP2009553136A patent/JP2010521437A/ja active Pending
- 2008-03-14 AR ARP080101092A patent/AR065778A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010521437A (ja) | 2010-06-24 |
CN101636153A (zh) | 2010-01-27 |
BRPI0808801A2 (pt) | 2014-08-19 |
EP2120888A1 (en) | 2009-11-25 |
US20100028426A1 (en) | 2010-02-04 |
RU2452472C2 (ru) | 2012-06-10 |
WO2008110577A1 (en) | 2008-09-18 |
EP1970056A1 (en) | 2008-09-17 |
RU2009138048A (ru) | 2011-04-20 |
AR065778A1 (es) | 2009-07-01 |
CA2679210A1 (en) | 2008-09-18 |
KR20090119986A (ko) | 2009-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6804790B1 (ja) | N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
EP2755648B1 (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
AU2008267058C1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
US20080317807A1 (en) | Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof | |
CN107406421A (zh) | sGC刺激物 | |
MX2009009862A (es) | Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico. | |
JP2001525359A (ja) | アミノチオール化合物を用いた、神経及び腎障害ならびに治療に伴う毒性の治療方法 | |
WO2009082459A3 (en) | Anti-aging composition containing resveratrol and method of administration | |
EP3248602A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae | |
BG106319A (bg) | Фармацевтични състави и използването им за предотвратяване на удар, диабети и/или конгестивна сърдечна недостатъчност | |
WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
US20180042956A1 (en) | Glutamate Dehydrogenase 1 Inhibitors and Methods of Treating Cancer | |
CN104603096A (zh) | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 | |
WO2011009714A3 (en) | Benzoquinolizinium salt derivatives as anticancer agents | |
CN102198108B (zh) | 一种盐酸西那卡塞片剂或胶囊制备工艺 | |
CN101098867A (zh) | 取代的亚砜类化合物和其制备方法及用途 | |
CN101917988A (zh) | 用于治疗和预防心脏病的药物组合物 | |
WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
CN109476686A (zh) | sGC刺激剂的磷前药 | |
JP2015143256A (ja) | 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤 | |
CN106667969A (zh) | 一种依匹哌唑缓释胶囊及其制备方法 | |
WO2009008004A3 (en) | Sustained release formulations of divalproex sodium | |
NZ596275A (en) | Burst drug release compositions | |
CN102958521A (zh) | 缓释性高血压和肾功能不全治疗剂 | |
CN101897682B (zh) | 一种伊伐布雷定或其可药用盐固体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |